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Abstract
The high-risk (HR) human papillomaviruses (HPV) are caus-
ative agentsof anogenital tract dysplasia and cancers anda fraction
of head and neck cancers. The HR HPV E6 oncoprotein possesses
canonical oncogenic functions, such as p53 degradation and
telomerase activation. It is also capable of stimulating expression
of several oncogenes, but the molecular mechanism underlying
these events is poorly understood. Here, we provide evidence that
HPV16 E6 physically interacts with histone H3K4 demethylase
KDM5C, resulting in its degradation in an E3 ligase E6AP- and
proteasome-dependent manner. Moreover, we found that
HPV16-positive cancer cell lines exhibited lower KDM5C protein
levels than HPV-negative cancer cell lines. Restoration of KDM5C
signiﬁcantly suppressed the tumorigenicity of CaSki cells, an
HPV16-positive cervical cancer cell line. Whole genome ChIP-seq
and RNA-seq results revealed that CaSki cells contained super-
enhancers in the proto-oncogenes EGFR and c-MET. Ectopic
KDM5C dampened these super-enhancers and reduced the
expression of proto-oncogenes. This effect was likely mediated
by modulating H3K4me3/H3K4me1 dynamics and decreasing
bidirectional enhancer RNA transcription. Depletion of KDM5C
or HPV16 E6 expression activated these two super-enhancers.
These results illuminate a pivotal relationship between the onco-
genic E6 proteins expressed by HR HPV isotypes and epigenetic
activation of super-enhancers in the genome that drive expression
of key oncogenes like EGFR and c-MET.
Signiﬁcance: This study suggests a novel explanation for why
infections with certain HPV isotypes are associated with elevated
cancer risk by identifying an epigenetic mechanism through
which E6 proteins expressed by those isotypes can drive expres-
sion of key oncogenes. Cancer Res; 78(6); 1418–30. 2018 AACR.
Introduction
The human papillomaviruses (HPV) are nonenveloped DNA
viruses that infect human epithelia tissues. Infection by the high-
risk (HR) types, HPV-16 and HPV-18, are the major causes of
anogenital carcinomas in women andmen, as well as a fraction of
head and neck cancer (1, 2). The early proteins E6 and E7 of the
HR HPVs are oncoproteins. Constitutive expression at high levels
can immortalize primary human epithelial cells and induce
tumors in animal models (3). The HR HPV E7 protein interacts
and destabilizes retinoblastoma tumor suppressor family (RB1
and RB2), rendering the host cells to bypass G0–G1 to S phase
controls (4). In concert with the dysregulated cell growth, the HR
HPV E6 protein forms a complex with the ubiquitin ligase E6AP
and the tumor suppressor p53, resulting in its destabilization. The
HR HPV E6 also interacts and destabilizes a number of other
proteins, such as MGMT, BAK, hADA3, TIP60 (5, 6), BRCA1 (7),
and caspase-8 (8). These interactionsbroadly affect host cell signal
transduction, chromatin remodeling, genome stability, and apo-
ptosis, suggesting that HPV-associated carcinogenesis involves a
coordinated targeting ofmultiple pathways. Certainly, additional
targets and pathways remain to be discovered.
As a noncanonical function, HR HPV E6 plays an important
role in regulating certain oncogene expression. For example, HR
HPV E6 increases the epidermal growth factor receptor (EGFR)
expression (9–11). Upregulation of EGFR has been reported in
cervical cancers; it contributes to cancer cell proliferation, migra-
tion, and invasion. Another highly expressed proto-oncogene in
cervical cancer is c-MET (12), which is known to promote the
occurrence anddevelopment of cervical cancer andhas prognostic
value (13). Given the fact that cervical carcinomas are caused by
persistent HR HPVs infection, elevated proto-oncogene expres-
sion is also possibly a consequence of theHRHPVs infection (14).
However, the molecular mechanisms underlying the upregula-
tion of these two proto-oncogenes are unknown.
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Oncoproteins may utilize transcription factors to maintain the
general transcriptionalmachinery and sustain the oncogenic state.
Although HR HPV16 E6 activates NF-kB (15), a complex that
regulates transcription to change the cellular environment, it
cannot explain the elevated proto-oncogene expression in cervical
cancers. Another emerging role in proto-oncogene activation is
the abnormal epigenetic modiﬁcations. DNA methylation, his-
tone modiﬁcations, nucleosome remodeling, and non-coding
RNA-mediated targeting regulate many biological processes that
are fundamental to the genesis of cancer (16). Because modiﬁca-
tions to DNA and histones are dynamically laid down and
removed by chromatin-modifying enzymes in a highly regulated
manner, these enzymes are frequently mutated or dysregulated in
various types of cancer (17). Histone lysine methylation is one of
manykey epigeneticmodiﬁcations. In general, histoneH3 lysine4
(H3K4), H3K36, and H3K79 methylation are gene-activation
marks, whereas H3K9, H3K27, and H4K20 methylation are
gene-repression modiﬁcations. Histone lysine methylation is
generated or erased by a number of histone methyltransferases
(HMT) or removed by histone demethylases. For example, H3K4
tri-methylation (H3K4me3) is mediated by MLL1, MLL2, MLL3,
MLL4, Ash2L, SETD1A, SETD1B,WDR5, and RBBP5, whereas it is
removed by histone demethylase KDM5A, KDM5B, and KDM5C
(18–20). Previous studies have shown that HR HPV E6 interacts
withbothhistonemethyltransferases (CARM1, SET7, andPRMT1;
ref. 21) and acetyltransferases (p300, hADA3, and Tip60; ref. 22);
but it is not always clear how these interactions induce changes in
chromatin structures or alter gene expression in cervical cancer.
Importantly, recent study suggested that, in cancer cells, enhancers
that normally control the signal-dependent expression of growth-
related genes are frequently dysregulated. Moreover, the genera-
tion and activation of super-enhancers can be a persistent regu-
latory element that drives the uncontrolled proliferation (23). A
number of super-enhancers have been identiﬁed in various types
of cancer, but it has not been reported in cervical carcinomas.
Here, we demonstrate that HPV16 E6, but not the non-onco-
genic HPV6b E6, interacts with KDM5C, a tumor suppressor (24)
and histone H3K4me2/3-speciﬁc demethylase, and, in the pres-
ence of E6AP, mediates its polyubiquitination at K1479, leading
to degradation in a proteasome-dependentmanner. Consistently,
ectopic expression of HPV16 E6 leads to a moderate H3K4
methylation alteration. We have also found that HPV16-positive
cervical cancer cell lines exhibit lower KDM5C protein levels than
HPV-negative cancer cell lines. Conversely, restoration of KDM5C
in CaSki cells, an HPV16-containing cervical cancer cell line,
signiﬁcantly suppresses its growth and invasion in vitro and
tumorigenesis in nude mice. By using systematic molecular anal-
yses, we show that CaSki cells contain both EGFR and c-MET
super-enhancers. Ectopic KDM5Cexpression reduces their activity
while KDM5C depletion increases their activities. Dramatically,
the presence of HPV16 E6 is sufﬁcient to upregulate the EGFR and
c-MET super-enhancers, further elevating the expression of these
two proto-oncogenes. We therefore propose that HR HPV E6
activates cervical cancer super-enhancers and promotes tumori-
genesis by targeting tumor suppressor KDM5C.
Materials and Methods
Vectors and plasmids
HPV16 E6, the N-terminal (1–43) and the C-terminal por-
tion (44–151) of HPV16 E6 were cloned into pEGFP-C1 for
mammalian cell expression. HPV16 E6 mutation constructs
were generated similarly. HPV16 E6 Y79N has a single substi-
tution at tyrosine at residue 79. HPV16 E6 F2V/P5R has double
substitutions. HPV16 E6 D149–151 mutation has deletion
of amino acids 149 to 151. In HPV16 E6 (1–43) and 16 E6
(44–151), the amino acids 1–43 and 44–151 are preserved,
respectively. The pHAGE vector carries a puromycin-resistance
cassette, conferring the transfected cells resistance to puromycin at
varying concentrations, hence enabling us to select and generate
stable cells. The KDM5C K1479R mutation was constructed by
overlapping extension during polymerase chain reaction-PCR
from the pHAGE-KDM5C plasmid. For bacterial expression of
fusion to the maltose binding protein (MBP), HPV16 E6 or
mutations were each cloned into pMAL-c2x vector. All the con-
structs were validated by DNA sequencing.
Cell culture and reagents
CaSki, C33A, SiHa, andHeLa cell lineswere purchased from the
ATCC between 2012 and 2014. HEK293T, HCT116, and U2OS
cell lines were obtained from Institute of Cellular Resources,
Shanghai Institutes for Biological Sciences, Chinese Academy of
Sciences in 2011 and 2015. All cell lines involved in our experi-
ments were reauthenticated by short tandem repeat analysis every
6months after resuscitation in our laboratory and routinely tested
to verify the absence of mycoplasma with LookOut Mycoplasma
PCR Detection Kit (Sigma). CaSki and C33A cell lines were
additionally tested for the presence of HPV16 by PCR before the
initiation of this study. The cells revived from frozen stocks were
used within 10 to 20 passages or for no longer than 2 months in
total for any experiment.
HCT116, HEK293T, C33A, and SiHa cells were cultured in
Dulbecco's Modiﬁed Eagle's Medium-DMEM (HyClone) supple-
mented with 10% fetal bovine serum (FBS, Gibco). CaSki, U2OS
cells were maintained in Roswell Park Memorial Institute-RPMI
1640 medium (HyClone) with 10% FBS (Gibco). Stable vector
(CaSki-pHAGE)-containing cells and KDM5C expressing CaSki
cells (CaSki-KDM5C) were generated by lentivirus transduction
and selected with puromycin. Brieﬂy, lentiviruses were generated
in HEK293T cells transfected with helper plasmids pMD2.G and
psPAX2, together with vector or KDM5C-expressing vector using
Lipofectamine 2000 (Invitrogen, 11668). CaSki cells were then
infected with lentivirus. Stably transduced cells were selected in
RPMI-1640 (HyClone) supplemented with 10%FBS (Gibco) and
2 mg/mL puromycin (Cayman Chemicals, 13884). Stable C33A
cell lines expressing vector (C33A-EGFP) or EGFP-HPV16 E6
(C33A-16E6) were established as described above. C33A cells
were subsequently infected with lentivirus and maintained in
DMEM (HyClone) medium with 4 mg/mL puromycin. These
cellswere cultured at 37C inahumidiﬁedatmosphere containing
5% CO2.
The CaSki KDM5C knockout (CaSki-KDM5C KO) cell line was
generated as described in Sanjana and colleagues (25). Lentivirus
carrying the guide RNA (gRNA) of KDM5C was produced as
mentioned above and used to infect CaSki cells. The lentiviral
based lentiCRISPRv2-KDM5C plasmid was kindly provided by
Yang Shi (Harvard University). Stable CaSki-KDM5C KO cells
were selected in appropriate complete medium supplemented
with 2 mg/mL puromycin. Single clones were established in the
absence of puromycin and knockout efﬁciency were periodically
conﬁrmed by Western blot. gRNA sequence used is KDM5C exon
1: 50-ACGATTTCCTACCGCCACC-30.
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RNA extraction and qRT-PCR
Total RNA was obtained from treated cell lines using TRIzol
(Invitrogen, 15596018) according to the manufacturer's instruc-
tions. For cDNA preparation, 1 mg of total RNA was reverse
transcribed for RT-PCR using All-in-One cDNA synthesis Super-
Mix (Biotool, B24403). The obtained cDNAwas ampliﬁedbyPCR
for 16E6expression analysis. ThePCRprimerswere designedwith
Primer Premier 5.0 software and GAPDH was used as a reference
gene. qPCR was performed on CFX Connect Real Time PCR
Detection System (Bio-Rad) using SYBR Green Real time PCR
Master Mix (Biotool, B21802). GAPDH ampliﬁcation products
were used as a control. All reactions were carried out in triplicates.
Data were analyzed by the 2DDCT method. Primer sequences
are detailed in Supplementary Table S1 in the Supporting
information.
RNA-seq and analysis
Total RNA was extracted from CaSki-pHAGE and CaSki-
KDM5C cells using TRIzol (Invitrogen, 15596018). Purity of RNA
samples was determined with NanoPhotometer Spectrophotom-
eter (Implen) and concentration was quantiﬁed in a Qubit 2.0
ﬂuorometer (Life Technologies). Sequencing libraries were con-
structedusing theNEBNextUltraDirectional RNALibrary PrepKit
for Illumina (NEB, E7420) and library quality was validated on
Bioanalyzer 2100 (Agilent Technologies). Clustered sequences
were generated using TruSeq SECluster Kit v3-cBot-HS (Illumina)
followed by sequencing on HiSeq 2500 (Illumina). Generated
reads were mapped to human genome (hg38) database using
TopHat v2.0.9. Gene expression levels and differential expression
were quantiﬁed with Cuffdiff v2.1.1. Threshold for differential
expression was set at FPKM  1 and P value < 0.05.
Chromatin immunoprecipitation-PCR and ChIP-Seq
See details in Supplementary section.
Primer sequences used in this assay were listed in Supplemen-
tary Table S2.
Xenograft assay
Five-week-old female BALB/c nude mice were acquired from
Beijing HFK Bioscience (Beijing, China) and housed under spe-
ciﬁc pathogen-free conditions in Animal Experiment Center-Ani-
mal Biosafety Level-III Laboratory of Wuhan University. The
animals were fed with standard laboratory mice diet and water
ad libitum. At 6thweek,mice were randomly divided into 2 groups
and injected with 100 mL of stable CaSki-pHAGE or CaSki-
KDM5C cells suspended in Matrigel Basement Membrane Matrix
(Corning, 356234) at a density of 5 106 cells into the left dorsal
ﬂank subcutaneously after alcohol sterilization of injection site
skin surface. Tumor size and body weight of each mice were
obtained once weekly using digital vernier caliper and electronic
scale, respectively. Tumor volume was calculated with the formu-
la: tumor volume (mm3) ¼length (mm)  width (mm2)  0.5.
Mice were sacriﬁced by cervical dislocation and tumors were
excised on 6th week after injection. All animal experiments
performed were approved by and conform to the guidelines of
Animal Research Ethics Board of Wuhan University.
The xenograft of CaSki KDM5C knockout cells (CaSki-KDM5C
KO) was performed as mentioned above, and CaSki cells were
used as control group.
Additional information is presented in Supplementary
Methods.
Sequencing data have been deposited in the Gene Expression
Omnibus(GEO) repository under accession code GSE101565.
Results
HPV16 E6 interacts with histone demethylase KDM5C
Previous studies showed that histone demethylase KDM5C
(also called SMCX or JARID1C) and histone acetyltransferase
TIP60 each forms a complex with HPV E2 protein to repress the
viral LCR promoter (26, 27). Conversely, the oncogenic and
non-oncogenic HPV E6 proteins interact with TIP60 and desta-
bilize it in a proteasome-dependent manner to de-repress the
LCR promoter (6). It is not known whether KDM5C could
also be targeted by HPV E6 in a similar manner. Because
HPV-induced malignancies are largely the result of protein–
protein interactions involving viral oncoproteins, we began our
studies by examining a possible interaction between HPV16 E6
and KDM5C.
First, we expressed EGFP-16 E6 fusion protein in HPV-negative
human cervical cancer cell line C33A. Coimmunoprecipitation
clearly showed that HPV16 E6 bound to endogenous KDM5C
(Fig. 1A). We also coexpressed EGFP-16 E6 and KDM5C in
HCT116 cells (epithelial cells derived from colorectal carcinoma)
and performed reciprocal coimmunoprecipitations. The result
also showed that KDM5C speciﬁcally bound to HPV16 E6 (Sup-
plementary Fig. S1). To rule out the possibility that EGFP itself
interacts with KDM5C, we performed coimmunoprecipitation by
coexpressing KDM5C and EGFP-16 E6 or EGFP in HCT116 cells.
The results showed that KDM5Cwas coimmunoprecipitated only
in the presence of EGFP-16 E6 but not EGFP (Fig. 1B). To conﬁrm
that HPV16 E6 interacted directly with KDM5C, we further con-
structed and puriﬁed the MBP-16 E6 fusion protein from E. coli.
We generated the ectopically and stably expressed KDM5C in
CaSki cells (CaSki-KDM5C). The puriﬁed MBP-16 E6 or MBP
protein was then incubated with CaSki-KDM5C cell lysates and
pulldown assays were performed. As shown in Fig. 1C, puriﬁed
MBP-16 E6 fusion protein but not MBP clearly interacted with
KDM5C.
HPV E6 protein interacts with cellular proteins via various
domains. For example, the S/TXVmotif at HRHPV E6C-terminus
interacts with PDZ domain–containing proteins, whereas the N-
terminus with p53. To delineate the HPV16 E6 domain, which
interacts with KDM5C, we constructed a series of MBP-fused
HPV16 E6 mutant forms and performed pulldown assays using
lysates of CaSki-KDM5C (Fig. 1D). As shown in Fig. 1E, F2V/P5R,
a double point mutation of HPV16 E6 protein, which is unable to
bind p53, interacted with KDM5C, as the wild-type protein did
(lane 3). The Y79N mutation, which abolishes the interaction
betweenHPV16 E6 and E3 ligase E6AP (24), did not inﬂuence E6-
KDM5C interaction (lane 5).Notably, the deletion of S/TXVmotif
at E6 C-terminus slightly attenuated the interaction (lane 4),
whereas the deletion of amino acid residues 44–151 completely
abolished the binding (lane 7). In fact, the expression of residues
44–151 retained the full binding activity (lane 6). These results
indicate that HPV16 E6 interacts with KDM5C via the central and
C-terminal portions of the protein, different from those that
interact with the p53 and PDZ family of proteins. Although
KDM5C does not contain PDZ and LXXLL motifs, a number of
HR HPV E6-binding cellular proteins, such as p53, Bak, p300/
CBP, hADA3, NFX1, Gps2, FADD, TIP60, and procaspase-8, do
not have these motifs either (8).
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We also constructed KDM5C truncation mutations and delin-
eated the domain of KDM5C responsible for 16E6 binding. Flag-
tagged wild-type and four mutant forms were each cotransfected
with theGFP-16 E6 vector intoHCT116 cells. The pulldown result
showed that C-terminal region of KDM5C is required for a stable
interaction with E6 (Fig. 1F and G).
HPV16 E6 destabilizes the KDM5C
HR HPV E6 disrupts normal cellular metabolism by dysregu-
lating gene expression, inactivating protein functions, or promot-
ing the target protein degradation.We thereforewanted to know if
HPV16 E6 could alter the KMD5C protein level. We examined the
KDM5C protein level by immunoblots in U2OS cells (epithelial
cells derived from osteosarcoma). The endogenous wild-type p53
was used as positive control for E6-target degradation. As shown
in Fig. 2A and B, in the presence of expression vector of EGFP-
HPV16 E6, but not the EGFP vector, the p53 protein level was
signiﬁcantly reduced. Notably, the endogenous KDM5C, but not
its family members KDM5A and KDM5B, exhibited a decreased
protein level. Similar results were obtained in HCT116 cells
(Supplementary Fig. S2A and S2B).
To analyze systemically the effect of HPV 16E6 motifs on
KDM5C stability, we expressed wild-type HPV 16E6 or various
HPV 16E6 mutations and detected the KDM5C protein level. As
shown in Fig. 2C, full-length HPV 16E6 expression eliminated
most of the KDM5C and p53, whereas the E6AP binding–
defective 16E6 mutation Y79N and 16E6 N-terminus (1–43)
failed to destabilize KDM5C or p53 (lanes 5 and 7). In contrast,
the 16E6 mutant F2V/P5R, a previously reported p53 binding–
defective mutant protein, was able to efﬁciently destabilize the
KDM5C, but not p53 (lane 3). Interestingly, the 16E6 (44–151)
led to a signiﬁcantly reducedKDM5Cbutnotp53protein (lane6).
These results were consistent with the pulldown assays as
described previously and indicate that an interaction of HPV16
E6 and KDM5C is important for KDM5C destabilization. We also
expressed GFP-E6 inHCT116 cells and performed indirect immu-
noﬂuorescence assay. As shown in Fig. 2D, the KDM5C protein
(red) was signiﬁcantly decreased in cells expressing EGFP-HPV16
Figure 1.
Identiﬁcation of interactions between HPV16 E6 and KDM5C. A, Coimmunoprecipitation of HPV16 E6 and KDM5C in cervical C33A cells overexpressing
E6 protein. B, Coimmunoprecipitation by coexpressing KDM5C and EGFP-16E6 or EGFP, respectively, in HCT116 cells to conﬁrm KDM5C interacts with HPV16 E6.
C, Interaction between HPV16 E6 and KDM5C in MBP pulldown assay performed with puriﬁed MBP-16E6 and CaSki-KDM5C cell lysates. D, Schematic
representation of HPV16 E6 mutation constructs. Descriptions of each construct are elaborated in Materials and Methods. E, Determining interactions
between KDM5C and mutated HPV16 E6. MBP pulldown assay performed with puriﬁed MBP fused HPV16 E6 wild-type or mutant forms of the 16E6 protein
and CaSki-KDM5C cell lysates. F, Schematic representation of KDM5C truncation constructs. G, Each KDM5C truncation construct was cloned into the
pHAGE vector harboring Flag-tag. Immunoprecipitation assays were carried out to determine interaction between each truncation construct with HPV 16E6;
KDM5C C-terminal region is required for interaction with HPV 16E6.
Human Tumor Virus and Cancer Super-Enhancer
www.aacrjournals.org Cancer Res; 78(6) March 15, 2018 1421
on July 9, 2019. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst January 16, 2018; DOI: 10.1158/0008-5472.CAN-17-2118 
E6 (green) relative to cells without HPV16 E6. Quantiﬁcation of
the KDM5CmRNA inHCT116 cells by qPCR showed it remained
unchanged in the presence or absence of ectopic HPV16 E6
(Supplementary Fig. S2C).
We then extended our investigation into cervical cancer cell
lines that are negative or positive for HR HPVs. As shown
in Fig. 2E, the KDM5C protein level in HPV-negative C33A
cells was clearly higher than that in two HPV16-positive cancer
cell lines, CaSki and SiHa, as well as one HPV18-positive
cancer cell line, HeLa. These results are in agreement with
previous observations with ectopic expression of HPV16 E6
in HPV-negative cell lines (Fig. 2A, B, and D). To rule out
the possibility that factors other than HPV16 E6 may have
led to the varied KDM5C levels in cervical cancer cell lines,
we transiently knocked down HPV16 E6 in CaSki cells.
Depletion of E6 increased both p53 and KDM5C protein
levels, reinforcing the idea that HPV16 E6 destabilizes KDM5C
(Fig. 2F).
HPV16 E6 promotes the KDM5C degradation via the ubiquitin
pathway
One of the most characterized properties of HPV16 E6 is its
ability to induce the tumor suppressor p53 degradation via the
ubiquitin pathway. Because HPV16 E6 destabilizes KDM5C,
which is another tumor suppressor identiﬁed in the recent years
(28), we explored if KDM5C was also degraded by a similar
mechanism.
First, we treated CaSki and C33A cells with the proteasome
inhibitor MG-132. As shown in Fig. 3A, the KDM5C protein level
increased in theHPV-positiveCaSki cells but not inHPV-negative-
C33A cells. The same result was observed when U2OS cells were
transfected with HPV16 E6 and exposed to MG-132. The KDM5C
protein level was comparable with that in cells not expressing
HPV16 E6 (Fig. 3B). These results indicate that HPV16 E6 desta-
bilizes KDM5C in a proteasome-dependent pathway. We next
asked that if E6AP plays the same role in the KDM5C degradation
as it does in destabilizing p53. Indeed, upon knocking down
E6AP, both p53 and KDM5C protein levels increased (Fig. 3C),
demonstrating that KDM5C is degraded by HPV16 E6/E6AP-
mediated proteasome activity, as is p53.
To validate our observation, we expressed EGFP, EGFP-HPV16
E6, or E6 truncation mutation forms along with HA-ubiquitin,
KDM5C in HCT116 cells. IP was performed with anti-KDM5C
and ubiquitin signal was detected with anti-HA in the presence of
MG-132. The presence of EGFP-HPV16 E6 and truncation muta-
tion E6 (44–151), but not the EGFPor the truncationmutation E6
(1–43), clearly showed polyubiquitination of KDM5C (Fig. 3D).
Thus, the E6 N-terminal portion is dispensable for KDM5C
polyubiquitination. To obtain further insights into the mecha-
nism of the KDM5C ubiquitination, the IP products were
Figure 2.
HPV16 E6 destabilizes KDM5C. A, U2OS cells transfected with vector or HPV16 E6. Immunoblot analyses were performed and expression changes were
detected using antibodies against p53, KDM5A, KDM5B, and KDM5C. B, Protein expression of KDM5A, KDM5B, and KDM5C in U2OS cells overexpressing
HPV16 E6 or vector was quantiﬁed based on blot intensities of three independent experiments in A. C, HPV16 E6 mutation constructs were cloned into pEGFP-C1
and transfected into HCT116 cells. Protein level changes of KDM5C and p53 were detected by immunoblot. D, Indirect immunoﬂuorescence microscopy was
performed in HCT116 cells overexpressing HPV16 E6. EGFP16 E6 (green), KDM5C (red), and DAPI (blue). Scale bars, 5 mm. E, KDM5C expression in four cervical
cancer cells was examined by immunoblots. F, KDM5C and p53 protein levels after siRNA targeting HPV16 E6 were introduced in CaSki cells.
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subjected to mass spectrometry analysis. The result revealed that
the lysine residue at 1479 of KDM5C was ubiquitinated only
when the HPV16 E6 was present (Fig. 3E). We subsequently
constructed KDM5CK1479Rmutant form and performed similar
analysis inHCT 116 cells. The K1479Rpointmutation eliminated
most of the polyubiquitination (Fig. 3F). We also cotransfected
HCT116 cells with Flag-WT KDM5C or K1479Rmutant form and
EGFP-HPV16 E6-expressing plasmids, the immunoblot results
showed thatWT KDM5C but not the K1479Rmutant was degrad-
ed (Fig. 3G). These results provide strong evidence that KDM5C is
a novel target of HPV16 E6 for polyubiquitin-dependent
degradation.
HPV16 E6-mediated KDM5Cdegradationmoderately alters the
global H3K4 methylation level
We speculated that HPV16 E6-caused KDM5C degradation
would result in increased tri- or dimethylation on H3K4. To
examine this possibility, we expressed HPV16 E6 in HCT116 cells
and examined trimethylation on several histone H3 lysine resi-
dues by immunoblots. Among various histoneH3 trimethylation
marks, H3K4me3, H3K27me3, and H3K36me3, only the
H3K4me3 level moderately increased, while H3K27me3 and
H3K36me3 remained unchanged in the presence of HPV16 E6
(Fig. 4A). Similar results were also obtained in U2OS cells
(Supplementary Fig. S3A). We then compared histone methyla-
tions in cervical cancer cell lines. Consistently, theHPV16-positive
CaSki cells exhibited a higher H3K4me3 level than the HPV-
negative C33A cells (Fig. 4B). Furthermore, we investigated the
H3K4 mono- and dimethylation level in response to HPV16 E6
expression in U2OS cells. We found that both H3K4 tri- and
dimethylation levels slightly increased, whereas the global
H3K4me1 alterationwas unchanged (Fig. 4C). However, an effect
of HPV16 E6 on the local H3K4me1 distribution could not be
ruled out. This issue will be addressed later.
To conﬁrm that KDM5Cdestabilization alone is responsible for
the increased H3K4me3, we ectopically expressed KDM5C in
U2OS cells. As shown in Supplementary Fig. S3B, expression
of HPV16 E6 increased the H3K4me3 level (lane 2), whereas
expression of KDM5C (lane 3), but not the empty vector
(lane 4), dramatically decreased H3K4me3. In contrast, ectopic
Figure 3.
HPV16 E6 promotes KDM5C degradation via the ubiquitin proteasome pathway. A, MG132-treated CaSki cells show increased KDM5C protein level as
comparedwith C33A cells.B,HPV16 E6was overexpressed in U2OS cells. KDM5C expression in cells with or without MG132 treatment was analyzed by immunoblots.
C, E3 ubiquitin ligase E6AP was knocked down by siRNA in CaSki cells; its effect on p53 and KDM5C protein level was evaluated by immunoblots.
D, Polyubiquitination assays were performed in HCT116 cells cotransfected with plasmids expressing HA-ubiquitin, KDM5C, HPV16 E6, HPV16 E6 mutants, or
vector. MG132was added to 10mmol/L for 4 hours prior to harvest.E, Lysates of ubiquitination assaywere subjected tomass spectrometry analysis. MS/MS spectrum
indicates KDM5C ubiquitination on lysine K1479. F, KDM5C mutation K1479R in which arginine was substituted for lysine is defective in HPV16E6-mediated
polyubiquitination. G, HPV16 E6 degrades wild-type KDM5C but not K1479R mutant. HPV16 E6 (2 mg) was cotransfected with 0.1 mg Flag-KDM5C wt or K1479R
mutant in HCT116 cells and the KDM5C protein level was detected using Flag tag antibody.
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coexpression E6 and p53 did not have additional effect on the
level of H3K4me3 (Supplementary Fig. S3C). Thus, the HPV16
E6-mediated KDM5C degradation plays a pivotal role in altered
global H3K4 trimethylation. To conﬁrm that KDM5C is an
essential regulator of global H3K4me3, we knock down
the KDM5C in CaSki cells. The depletion of KDM5C leads
to increased H3K4me3 without affecting the p53 protein level
(Fig. 4D).
The HR HPV E6 proteins destabilize many host cell proteins
(8). In contrast, the "low-risk" (LR) HPV E6 proteins do not
appear to possess such ability. To clarify if the HPV16
E6-mediated KDM5C degradation is shared with the LR HPV
types, we separately expressed EGFP-HPV16 E6 and EGFP-HPV6b
E6 inU2OS cells. Immunoblots with EGFP antibody revealed that
16E6, but not 6bE6, promoted the KDM5C degradation along
with an increased in H3K4me3 (Fig. 4E). These results suggest
that KDM5C destabilization is probably an important HR HPV
E6-mediated oncogenic event.
Restoration of KDM5C signiﬁcantly suppresses the
tumorigenicity of CaSki cervical cancer cells
We next wanted to know the signiﬁcance of KDM5C destabi-
lization and whether this event contributed to tumorigenesis. To
achieve the goal, we used the CaSki-KDM5C stable cell line with
elevatedKDM5Cprotein (Fig. 5A).We found that ectopic KDM5C
resulted in slightly decreased 16E6/E7 mRNA, but there was no
obvious change in 16E6/E7 and p53 protein levels (Supplemen-
tary Fig. S4A and S4B). We ﬁrst examined these cells for several
properties in vitro.When comparingwith the parental cells, CaSki-
KDM5C exhibited a reduced growth rate (Fig. 5B), a decreased
wound closure (Fig. 5C), and a lowered migration rate in Trans-
well (Fig. 5D). Lastly, amouse xenograft tumormodelwas used to
determine the effects of KDM5Coverexpression on tumorigenesis
in vivo. The results showed that comparedwithCaSki cells contain-
ing the vector control, tumors that derived from CaSki-KDM5C
grewmore slowly and were smaller (Fig. 5E and F). Immunoblots
conﬁrmed the elevated KDM5C in CaSki-KDM5C in tumor xeno-
grafts without affecting the p53protein level (Fig. 5G). To conﬁrm
the role of KDM5C as a tumor suppressor in cervical cancer, we
also generated xenograft by using CaSki cells in which KDM5C
was knocked out by using the CRISPR-Cas9. The depletion of
KDM5C signiﬁcantly promotes the tumor growth (Supplemen-
tary Fig. S5A–S5D). These results strongly suggest that KDM5C
plays an important role in cervical carcinoma growth in vivo.
Whole genome ChIP-seq revealed existence of the EGFR and
c-MET super-enhancers in the human cervical cancer cell line
A recent study revealed that KDM5C acts as a key regulator of
super-enhancers by controlling dynamics betweenH3K4me1 and
H3K4me3, and that loss of such enhancer surveillance may
contribute to tumorigenesis (29). Super-enhancer is a group of
densely clustered active enhancers, highly associated with cell
identity genes and disease-associated genomic variations (30). As
an attribute of being highly active or transcribed, the screening of
tumor-speciﬁc super-enhancers and the relevant functional study
are now of intense interest (23). Our ﬁnding in vitro and in vivo
(Fig. 2–5) prompted us to propose that KDM5C restoration may
inhibit the tumorigenicity of CaSki cervical cancer cells by damp-
ening speciﬁc super-enhancer status.
To test this hypothesis, we screened for the existence of possible
super-enhancers by carrying out chromatin immunoprecipitation
sequencing (ChIP-seq) analysis of H3K27Ac, one of the most
important and characterized features of enhancer, in the CaSki
cells, as well as the CaSki-vector control and CaSki-KDM5C cells.
Figure 4.
HR HPV16 E6 moderately alters the
global H3K4 methylation level.
A, HPV16 E6 or vector was ectopically
expressed in HCT116 cells.
Trimethylation marks of Histone H3
were determined by immunoblot.
B, Endogenous HPV16 E6 is expressed
in CaSki cells, hence the increase
in H3K4me3 in comparison with
HPV16-negative C33A cells. C, H3K4
mono-, dimethylation, and
trimethylation levels in response to
HPV16 E6 expression in U2OS cells.
D, Expression change of H3K4me3
upon KDM5C knockdown. siRNA
knockdown of KDM5C increases
H3K4me3 level, and p53 protein level
remains unchanged. E, KDM5C and
H3K4me3 level analysis in HPV16 E6,
the LR HPV6b E6, or vector-
overexpressing U2OS cells.
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By using the ROSE algorithm mainly based on the ranking of
H3K27Ac intensities (31), we identiﬁed a total of 313 super-
enhancers in parental cells. Dramatically, we found two proto-
oncogenes, EGFR and c-MET, each contained a super-enhancer.
The EGFR super-enhancer is located in the ﬁrst intron while the c-
MET super-enhancer resides within the c-MET gene 50 region
through intron 2 (Fig. 6A; Supplementary Figs. S6 and S7A). In
the ChIP-seq results of CaSki-vector and Caski-KDM5C, we also
found the same two super-enhancer regions (Fig. 6B), indicating
that our determination of EGFR and MET super-enhancers in
these cervical cancer cell lines was reproducible. Our results are
highly similar to an early study that three adjacent enhancers
clustered within the EGFR gene 50 region down to the intron 1
(32). Moreover, a recent study also identiﬁed an EGFR super-
enhancer in the ﬁrst intron in A549 lung cancer cells (33).
To validate the results, we compared the human LHCN-M1 cell
H3K27Ac ChIP-seq data (from https://www.ncbi.nlm.nih.gov/
geo/, GSM2068356) with our data from CaSki cells. The result
clearly showed that H3K27Ac signals in these two super-enhancer
regions matched well (Supplementary Fig. S7A). In addition,
chromatin landscape analysis through dbSUPER (www.bioinfo.
au.tsinghua.edu.cn/dbsuper) revealed high levels of H3K27
acetylation (H3K27Ac) across these regions, thus strongly sug-
gesting the existence of super-enhancer (Supplementary Fig. S7B).
These results encouraged us to determine the H3K4 methylation
status and enhancer RNA (eRNA) expression proﬁles of the super-
enhancers and to explore if KDM5C regulates these super-
enhancer activities.
KDM5C regulates cervical cancer cell EGFR and c-MET
expression by modulating their super-enhancer H3K4
methylation dynamics
To determine the whether and how KDM5C may modulate
EGFR and c-MET transcription via their super-enhancers, we
performed the ChIP-qPCR of KDM5C. Interestingly, KDM5C
were enriched at two distinct selected sites (sites 1 and 2) of the
super-enhancer regions of those two genes and the restoration of
KDM5C further promoted its enrichment (Fig. 6C and D; Sup-
plementary Fig. S7A), displaying a direct correlation between
them. In contrast, the region adjacent to super-enhancer (site 3)
showed much lower KDM5C enrichment, and ectopic KDM5C
expression failed to stimulate the enrichment. In general, for a
Figure 5.
Restoration of KDM5C inhibits tumorigenesis in cervical carcinoma. A, Protein levels of KDM5C in the parental CaSki, CaSki transfected with vector (CaSki-pHAGE),
and CaSki-KDM5C cells were examined by immunoblot. B, Cell proliferation was determined by using real-time cell proliferation assay. Cervical cancer cell
overexpressing KDM5C exhibited a reduced cellular growth rate. C, Migrating capability of the parental CaSki, CaSki-vector, and CaSki-KDM5C cells was
determined by wound-healing assay. Images were gathered at intervals of 0, 12, 24, 36 hours (magniﬁcation, 40). D, Transwell assays of parental CaSki,
Caski-vector, and CaSki-KDM5C cells to examine cell invasion. Cells were stained with crystal violet (magniﬁcation, 100). E and F, Xenograft growth (42 days;
n ¼ 10) analysis of CaSki-vector and CaSki-KDM5C cells. Representative images of the tumors (E) and quantiﬁcations of tumor volume (F) are shown. The animal
protocols were approved by the Animal Welfare Committee of Basic Medical College, Wuhan University. G, Immunoblots to examine KDM5C and p53 protein
level changes in tumor xenografts.
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super-enhancer, H3K4me1 is combined with H3K27Ac to further
deﬁne active enhancers (34). The dynamics between H3K4me1
versus H3K4me3 is also a determinant in the super-enhancer
activity (29). To gain further insight into themechanism regarding
how KDM5C restoration might modulate the proto oncogene
expression, we performed ChIP-seq of H3K4me3 and H3K4me1.
H3K4me1 overlapped the H3K27Ac signal (Fig. 6B), again val-
idating our super-enhancer analysis. When KDM5C was over-
expressed, H3K4me3 decreased while H3K4me1 increased in
selected super-enhancer regions (Fig. 6B), in agreement with the
known enzymatic activity of KDM5C. The H3K4me3/H3K4me1
alterationwas supported by ChIP-qPCR analyses in CaSki derived
cells (Fig. 6E and F). The H3K4me3/H3K4me1 dynamics obser-
vation implies that KDM5C restoration may have dampened
speciﬁc super-enhancer status. Our result also revealed that
KDM5C restoration led to speciﬁc increased H3K4me1 in global
super-enhancers rather than in adjacent regions (Supplementary
Fig. S8), conﬁrming KDM5C as a speciﬁc enhancer regulator.
Other aspects, such as the transcription of nearby gene and
bidirectional enhancer RNA (eRNA) transcription, are the impor-
tant features to determine if the super-enhancer is active or
overactive (35). First, in CaSki KDM5C cells, both EGFR and
c-METmRNA levels were signiﬁcantly downregulated, indicating
that KDM5C indeed negatively regulates their expressions (Fig.
6G). Next, we did RNA-seq to determine the eRNA transcription.
Both regions were bidirectionally transcribed into RNA, a well-
known feature of active super-enhancers. The data showed that
KDM5C restoration greatly decreased eRNAs transcribed from the
super-enhancer (Fig. 6B), consistent with the decreased EGFR and
c-MET mRNA expression (Fig. 6G). The reduction in KDM5C-
mediated eRNA transcriptionwas also readily conﬁrmed by qPCR
of three selected eRNAs (Fig. 6H and I). TheH3K4me1/H3K4me3
dynamic change, combined with the results of eRNA analysis,
target gene mRNA expression, and KDM5C super-enhancers
enrichment, strongly suggests that KDM5C restoration signiﬁ-
cantly suppresses the EGFR and c-MET super-enhancer activities.
KDM5C depletion further activates the EGFR and c-MET super-
enhancers
To mimic the HPV16 E6-mediated KDM5C degradation, we
knocked down the KDM5C expression by using the siRNA in
CaSki cells (Fig. 4D). In contrast to ectopic KDM5C expression,
Figure 6.
KDM5C regulates super-enhancers activity and gene expression of the EGFR and c-MET. A, Schematic representation of EGFR and c-MET super-enhancer.
B, ChIP-seq result shows H3K4, H3K27 methylation states in parental CaSki, CaSki-vector, and CaSki-KDM5C cells. The RNA-seq results indicate eRNAs
decreased at EGFR and c-MET super-enhancers in CaSki-KDM5C cells. C and D, KDM5C were enriched at super-enhancer or other regions of EGFR and c-MET
as veriﬁed by ChIP-qPCR. E and F, ChIP-qPCR data show that KDM5C restoration led to H3K4me3/ H3K4me1 alteration of EGFR and c-MET super-enhancers
in CaSki-vector and CaSki-KDM5C cells. G, EGFR and c-MET mRNA levels in CaSki cell with or without KDM5C restoration. H and I, Ectopic KDM5C
expression-mediated eRNA transcription reduction of EGFR and c-MET genes was conﬁrmed by qPCR of three selected super-enhancer–derived eRNAs in the
CaSki-vector and CaSki-KDM5C cells. J, mRNA expression of EGFR and c-MET in CaSki- and KDM5C-depleted CaSki cells was examined by RT-qPCR. K and L,
The eRNA transcription levels at EGFR and c-MET super-enhancers were examined by qPCR of three selected super-enhancers in parental CaSki- and
KDM5C-depleted CaSki cells. In all panels, qPCR data are represented as mean  SD from three biological replicates.  , P < 0.05;  , P < 0.01; t test.
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the depletion of KDM5C increased the mRNA expression of both
EGFR and c-MET genes (Fig. 6J). In breast cancer cells, the absence
of KDM5C promotes several oncogenes expression by switching
their super-enhancers status from active to over-active (29). We
thereforemeasured the eRNA transcription from EGFR and c-MET
super-enhancers. As shown in Fig. 6K and L, the three selected
super-enhancer–derived eRNAs all exhibited higher transcription
levels upon KDM5C depletion, demonstrating the importance
of KDM5C in suppressing the expression of the two proto-
oncogenes.
Expression of HPV16 E6 activates the super-enhancers by
degrading KDM5C
Because HPV16 E6 is able to destabilize KDM5C, a key regu-
lator of super-enhancer, we reasoned that the presence of HPV16
E6 would directly activate the super-enhancers. It follows that
HPV16 E6 knockdown in CaSki cells would lead to decreased
EGFR and c-MET gene expression. Because E6 is critical for the
survival of cervical cancer cells (36, 37), we can only knock down
E6 by a moderate amount. In these experiments, we indeed
observed a moderate reduction in EGFR and c-MET expression
(Supplementary Fig. S9A). To substantiate this hypothesis, we
stably overexpressed HPV16 E6 in C33A cells. The results show
KDM5C degradation and increased expression of EGFR and
c-MET (Fig. 7A and B). We then conducted ChIP-qPCR to deter-
mine the KDM5C, H3K4me1, H3K4me3 signals on super-enhan-
cers in these cells. The presence of HPV16 E6 decreased the
KDM5C recruitment to super-enhancers of both proto-oncogenes
(Fig. 7C), presumably because of the reduced KDM5C protein
level. Accordingly, H3K4me1 decreased while H3K4me3
increased (Fig. 7D and E). We suggest that the super-enhancers
switched from "active" to "overactive" status, resulting in further
elevated EGFR and c-MET mRNAs. Lastly, we examined eRNA
transcription. As indicated in Fig. 7F and G, in the presence of
HPV16 E6, the eRNA transcription clearly increased, reminiscent
of KDMC5 depletion (Fig. 6). However, when HPV16 E6 and
KDM5C were coexpressed in C33A cells, the level of KDM5C
protein increased, accompanied by a reduction in EGFR and
c-MET transcription (Fig. 7A and B). Furthermore, the coexpres-
sion of KDM5C also reduced the eRNAs expression level (Fig. 7F
and G). Consistent with these results, upon knocking down
HPV16 E6 in CaSki cells, eRNA transcription was markedly
suppressed (Supplementary Fig. S9B and S9C), indicating that
HPV16 E6 was able to activate the oncogene super-enhancers by
degrading KDM5C.
Because E6 is a multifaceted protein, to rule out the possibility
that E6 activate super-enhancers through other proteins, we
knocked down KDM5C in HPV-negative cervical cancer cells
C33A (Supplementary Fig. S9D), both EGFR and c-MET gene
expression were upregulated upon KDM5C depletion (Supple-
mentary Fig. S9E), as well as their super-enhancers eRNA tran-
scription (Supplementary Fig. S9F and S9G). These results rein-
forced the idea KDM5C is the key super-enhancer regulator in
cervical cancer cells and its degradation byHPV16 E6 activates the
super-enhance and elevates the expression of EGFR and c-MET.
Discussion
The HR HPV E6 and E7 oncoproteins are involved in multiple
biochemical activities, including destabilizing tumor suppressors,
such as pRB, p53, andTIP60.However, these activities are not able
to account for HPV-caused cancers completely. Therefore, it is of
interest to identify novel cellular factors that play a role in HPV
carcinogenesis. In addition, HPV oncoproteins alter the gene
expression, such as KDM6A (38), OGT (39), EGFR, c-MET, as
well as a number of miRNAs (40), probably via unknown epi-
genetic mechanisms. For instance, HPV E6 has been shown to
target several histone modifying enzymes, such as p300 (41),
TIP60, CARM1, PRMT1, and SET7, but until now there was no
direct correlation between the host transcription alteration and
HPV induced epigenetic change. KDM5C is a novel tumor sup-
pressor identiﬁed in renal andbreast cancers (29, 42). This protein
has been shown to suppress the LCR promoter and inhibit E6/E7
expression by forming a complex with the HPV E2 protein, in a
manner highly similar to the E2–TIP60 interaction (27). How-
ever, HPV E2 and related proteins are not expressed in HPV
cancers in which the viral DNA has integrated into the host
chromosomes, disrupting the E2 transcription unit (43, 44).
Here, we show that HPV E6 destabilizes KDM5C in a protea-
some-dependent pathway, as has been shown for TIP60 (6).
However, unlike TIP60 destabilization by LR and HR HPV E6
proteins, our result reveals that the HR HPV16 E6, but not the LR
HPV E6, mediates KDM5C degradation (Fig. 4D). This activity
appears to have an important role in tumorigenesis. We demon-
strate that the KDM5C restoration via ectopic expression signif-
icantly inhibits cervical cancer cells growth in nudemice (Fig. 5). A
recent study suggested that loss of KDM5C results in further
activation of their target enhancers, thereby promoting tumori-
genesis of breast cancer cell (29).
Even though the destabilization of both KDM5C andp53 by E6
is mediated by the E6AP ubiquitin ligase, the domain of E6,
critical to these two activities, is different. Using p53 as an internal
control in our domainmapping experiment, we showed that full-
length HPV16 E6 expression eliminated most of the KDM5C and
p53, while the E6AP binding–defective 16E6 mutant Y79N and
16E6 N-terminal domain 1–43 failed to cause the degradation of
either KDM5C and p53 (Fig. 2C, lanes 5 and 7). In contrast, the
16E6 mutation F2V/P5R, a previously reported p53 binding–
defectivemutation, indeed did not destabilize p53; but it was able
to destabilize efﬁciently the KDM5C (lane 3). Similarly, the 16E6
C-terminal domain 44–151 retains the KDM5C interacting activ-
ity, resulting in signiﬁcantly reduced KDM5C; but it was not able
to destabilize p53 protein (lane 6). These results suggest that
although the HPV16 E6 is capable of mediating both p53 and
KDM5C degradation in a E6AP-dependent pattern, distinct HPV
16E6domains function in these twoprotein destabilizationbased
on their interaction with p53 or KDM5C, respectively. For p53
degradation, the HPV16 E6 N terminal region is required, while
the C-terminal domain is more critical for KDM5C destabiliza-
tion. Our study also showed that HPV16 E6 does not destabilize
KDM5A and KDM5B (Fig. 2A; Supplementary Fig. S2A). KDM5A,
B, and C share similar domains in the N-terminus. However,
KDM5C C-terminus is shorter and contains only one PHD
domain while KDM5A and KDM5B each has two. Interestingly,
KDM5C interacts with HPV16 E6 through the C-terminus. Thus,
the unique KDM5C C-terminus may help explain why only
KDM5C but not its other family members is able to interact with
HPV16 E6.
A number of super-enhancers have been identiﬁed in various
types of cancer; however, they have not been identiﬁed in cervical
cancer. In elucidating the role andmechanism of KDM5C activity
in cervical cancer, we discovered that KDM5C is enriched on EGFR
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and c-MET, twooverexpressed proto-oncogenes in cervical cancer.
By systematically analyzing the cervical cancer cells for histone
modiﬁcations H3K27Ac and H3K4me1/3, as well as the eRNA
and mRNA transcription in these two genes, we have established
that EGFR and c-MET each contain a super-enhancer. KDM5C
controls the super-enhancers activity by regulating theH3K4me1/
H3K4me3 dynamics and eRNA transcription (Fig. 6). Important-
ly, HPV16 E6 is capable of activating the super-enhancers activity
by promoting the KDM5C degradation (Fig. 7). To our knowl-
edge, it is the ﬁrst report linking the HPV E6 oncoprotein directly
to super-enhancer activation via changes in epigenetic modiﬁca-
tions.Our studyhelps explainwhy theHPVE6oncoprotein is able
to upregulate the host cell oncogene expression.
Taken together, we suggest that overactive super-enhancersmay
be of one of the driving forces in cervical cancer tumorigenesis,
and that the HR HPV16 E6 is responsible for this process.
Figure 7.
HPV16 E6 directly activates super-enhancers by degrading KDM5C. A, KDM5C protein levels in C33A cells coexpressing HPV16 E6 and KDM5C were examined
by immunoblots. B, EGFR and c-MET mRNA levels in stable KDM5C-expressing C33A, C33A-16 E6, C33A-vector were measured by RT-qPCR. C, Decreased
KDM5C binding at super-enhancer regions of EGFR and c-MET in C33A-16 E6 cell lines as conﬁrmed by ChIP-qPCR. D and E, H3K4 methylation state alterations at
super-enhancer regions of EGFR and c-MET in C33A-16 E6 cells relative to C33A-vector cells by ChIP-qPCR. F and G, eRNA transcription levels at EGFR and c-MET
super-enhancers were examined by qPCR of three selected super-enhancers in the stable C33A-GFP (vector), C33A-16 E6 cells, and KDM5C-expressing C33A-16 E6
cells. In all panels, qPCR data are represented as mean  SD from three biological replicates.  , P < 0.05;  , P < 0.01; t test. H, Model for HPV16 E6 provoked
cervical cancer speciﬁc super-enhancers activation. HPV16 E6 binds to KDM5C and forms an E6–E6AP–KDM5C complex, which degrades KDM5C in an
ubiquitin-dependent manner. As a consequence, key proto-oncogenes increase expression due to the activation of super-enhancers, thereby promoting
tumorigenesis.
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Collectively, based on our results and previous study, we generate
a model as shown in Fig. 7H, HPV16 E6 binds to KDM5C and
form an E6–E6AP–KDM5C complex, thereby degrading KDM5C
in a polyubiquitin-dependent manner. As a result, the super-
enhancers of key proto-oncogenes, EGFR and c-MET, become
highly upregulated, increasing their expressions and promoting
tumor cell growth.
Ourﬁndingsmay also provide useful clues to anewmechanism
for other pathogen-associated cancers, namely, the regulation of
super-enhancer. For example, thehepatitis B virus Xprotein (HBx)
can physically interact with histone acetyltransferase CBP/p300
and promote the expression of PCNA and IL8 (45, 46). Because
CPB/p300 catalyze H3K27Ac, a histone hallmark of enhancer, it
mayworth exploring the effect of the hepatitis B virus Xprotein on
liver cancer super-enhancer formation or activation. In another
pathogen-associated cancer, the cytotoxin-associated gene A
(CagA) of H. pylori has a pathophysiologically important role in
gastric carcinogenesis. CagA enhances the expression of DNA
methyltransferases 3B (DNMT3B) and histone methyltransferase
enhancer of zeste homologue 2 (EZH2), resulting in the attenu-
ation of let-7 expression regulated by histone and DNA methyl-
ation (47). Our ﬁnding could imply thatH. pylori proteins possess
the potential to inﬂuence the generation ormodiﬁcation of gastric
cancer super-enhancers.
In summary, we demonstrate that oncogenicHPV16 E6protein
activates cancer super-enhancers. This ﬁnding has provided novel
insights into virus-induced cancer. We suggest that these discov-
eries could contribute to the development of targeted cancer
therapy.
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